NO991194L - Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid - Google Patents

Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid

Info

Publication number
NO991194L
NO991194L NO991194A NO991194A NO991194L NO 991194 L NO991194 L NO 991194L NO 991194 A NO991194 A NO 991194A NO 991194 A NO991194 A NO 991194A NO 991194 L NO991194 L NO 991194L
Authority
NO
Norway
Prior art keywords
alfa
methoxyimino
azabicyclo
oct
controlled
Prior art date
Application number
NO991194A
Other languages
English (en)
Norwegian (no)
Other versions
NO991194D0 (no
Inventor
Susan Marie Milosovich
William Muldoon
Joseph Sauer
James Albert Napper
Laurence Rousseau
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO991194D0 publication Critical patent/NO991194D0/no
Publication of NO991194L publication Critical patent/NO991194L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO991194A 1996-09-12 1999-03-11 Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid NO991194L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (fr) 1996-09-12 1997-09-08 Formulation a liberation lente de monohydrochlorure de [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile

Publications (2)

Publication Number Publication Date
NO991194D0 NO991194D0 (no) 1999-03-11
NO991194L true NO991194L (no) 1999-03-11

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991194A NO991194L (no) 1996-09-12 1999-03-11 Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid

Country Status (22)

Country Link
EP (1) EP0929301A2 (fr)
JP (1) JP2001500150A (fr)
KR (1) KR20000036039A (fr)
CN (2) CN1235544A (fr)
AR (1) AR008176A1 (fr)
AU (1) AU724086B2 (fr)
BR (1) BR9711734A (fr)
CA (1) CA2265661A1 (fr)
CO (1) CO5031291A1 (fr)
CZ (1) CZ83299A3 (fr)
GB (1) GB9619074D0 (fr)
HU (1) HUP9904401A3 (fr)
ID (1) ID19589A (fr)
IL (1) IL128781A0 (fr)
MA (1) MA24359A1 (fr)
NO (1) NO991194L (fr)
NZ (1) NZ334268A (fr)
PE (1) PE2499A1 (fr)
PL (1) PL332074A1 (fr)
TR (1) TR199900505T2 (fr)
WO (1) WO1998010762A2 (fr)
ZA (1) ZA978133B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
TR200002626T2 (tr) 1998-03-11 2001-03-21 Smithkline Beecham Plc Terkip
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
PE20040134A1 (es) 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
WO2004096208A1 (fr) * 2003-04-25 2004-11-11 Mitsubishi Pharma Corporation Composition pour administration orale contenant un derive d'alkylene dioxybenzene
ES2273271T5 (es) * 2003-05-14 2013-05-21 Aptalis Pharma Limited Composición de liberación controlada de fármaco resistente a la tensión mecánica in vivo
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
SI1789021T1 (sl) 2004-08-13 2012-02-29 Boehringer Ingelheim Int Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol
CN101849920A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
EP1970056A1 (fr) * 2007-03-15 2008-09-17 Polichem S.A. Formules de dosages à libération retardée/pulsatile spécifique au temps
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
AU2020257406A1 (en) * 2019-04-19 2021-12-16 Hoffman Technologies Llc Sustained release formulations
WO2026013566A1 (fr) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. Nouvelles formes salines de sabcoméline
WO2026013570A1 (fr) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. Nouvelles formes salines de sabcoméline
WO2026013573A1 (fr) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. Nouvelles formes salines de sabcoméline
WO2026013563A1 (fr) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. Nouvelles formes salines de sabcoméline
WO2026018155A1 (fr) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinaisons de sabcoméine avec des antagonistes muscariniques pénétrant dans le système nerveux non central à action prolongée
WO2026018154A1 (fr) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Associations de sabcoméline et d'antagonistes muscariniques ne pénétrant pas dans le snc

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
CA2265661A1 (fr) 1998-03-19
CN1235544A (zh) 1999-11-17
PL332074A1 (en) 1999-08-30
TR199900505T2 (fr) 1999-06-21
WO1998010762A3 (fr) 1998-06-04
HUP9904401A3 (en) 2001-03-28
MA24359A1 (fr) 1998-07-01
NZ334268A (en) 2000-10-27
KR20000036039A (ko) 2000-06-26
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
GB9619074D0 (en) 1996-10-23
AR008176A1 (es) 1999-12-09
AU724086B2 (en) 2000-09-14
NO991194D0 (no) 1999-03-11
BR9711734A (pt) 1999-08-24
ZA978133B (en) 1999-04-12
PE2499A1 (es) 1999-03-24
WO1998010762A2 (fr) 1998-03-19
AU4128897A (en) 1998-04-02
JP2001500150A (ja) 2001-01-09
ID19589A (id) 1998-07-23
CZ83299A3 (cs) 1999-08-11
CO5031291A1 (es) 2001-04-27
EP0929301A2 (fr) 1999-07-21
CN1446535A (zh) 2003-10-08

Similar Documents

Publication Publication Date Title
NO991194L (no) Kontrollert-frigj°ring doseform av [R-(Z)-&lt;alfa&gt;-(metoksyimino)-&lt;alfa&gt;-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid
KR100246065B1 (en) Substituted 3-aminoquinuclidines
UA41355C2 (uk) Засіб для лікування нейро-сніду
EE04854B1 (et) Oksabispidiinühendid, nende valmistamise meetod ning ravimvorm kasutamiseks südame arütmia raviks ja profülaktikaks
NO995794L (no) Farmasoeytisk preparat inneholdende &#34;Lactobacillus casei rhamnosus&#34;
EP0497258A3 (en) Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer
MY110110A (en) Pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and cns disorders
NO864336L (no) Fremgangsmaate for fremstilling av terapeutisk aktive n-substituerte-n-(3-(1,2,4-triazolo(4,3-6)pyridazin-6-yl)fenyl)alkanamider,-karbamater og -urinstoffer.
BG103474A (en) Application of derivatives of 7-(2-oxa-5,8-diazobicyclo[4,3,0]non-8-8-yl)-quinoloncarboxylic acid and naphthyridoncarboxylic acid in the therapy of helicobacter pylor infections and the gastroduodenal diseases related to them
NO922426D0 (no) Forbindelser med reninhemmende egenskaper, fremgangsmaate for fremstilling av disse og deres anvendelse
EP1542672A4 (fr) R-bambuterol, sa preparation et ses utilisations therapeutiques
NO972582L (no) Anvendelse av teofyllinderivater, for behandling og profylakse av sjokktilstander, nye xantanforbindelser og deres fremstilling
MX9300927A (es) Compuestos terapeuticos de triazina y su empleo.
EE200300495A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
TR199900141T2 (xx) Bunama tedavisi ve/veya profilaksisi i�in form�lasyon.
EE200300506A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
ZA931099B (en) Heterocyclic compounds their use and preparation
NO910372D0 (no) Fremgangsmaate for fremstilling av heksahydropyrrolo(2,3-b)indolkarbamater-, urea-, amider og beslektede forbindelser og deres anvendelse som medikamenter.
WO2000032176A3 (fr) Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose
WO1999015160A3 (fr) Utilisation de 2-aminotetralines 6,7-substituees pour la preparation de compositions pharmaceutiques pour le traitement de pathologies inflammatoires et/ou auto-immunes
PE128999A1 (es) 1,2,4-triazolo[3,4-a]piridazina sustituida
NO914654D0 (no) Fremgangsmaate for fremstilling og anvendelse av beta-hydroksyetylaminer med 1,1-disubstituert cyklopropylrest
KR900007413A (ko) 에이즈 발병방지, 치료제 및 그 치료용 조성물
NO950842L (no) Diarylpiperazinoacetamidforbindelser som antimuskariniske midler